Repeated intermittent methylenedioxymethamphetamine exposure protects against the behavioral and neurotoxic, but not hyperthermic, effects of an MDMA binge in adult rats

Synapse

Volumn 64, Issue 6, 2010, Pages 421-431

  Piper, Brian J ^a,c   Ali, Syed F ^b   Daniels, Lauren G ^a,d   Meyer, Jerrold S ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

Behavior; Body weight; Ecstasy; Ejaculation; Preconditioning; SERT

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; CITALOPRAM; SEROTONIN; SEROTONIN TRANSPORTER; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORE TEMPERATURE; DRUG EXPOSURE; DRUG SENSITIVITY; DRUG SENSITIZATION; HIPPOCAMPUS; HYPERTHERMIA; LOW DRUG DOSE; MALE; MOTOR ACTIVITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT;

AGE FACTORS; ANIMALS; BINDING, COMPETITIVE; BODY TEMPERATURE; CEREBRAL CORTEX; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEVER; HIPPOCAMPUS; HYDROXYINDOLEACETIC ACID; MALE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXINS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 77952899690     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20744     Document Type: Article

References (49)

1. Aberg M, Wade D, Wall E, Izenwasser S. 2007. Effect of MDMA (ecstasy) on activity and cocaine conditioned place preference in adult and adolescent rats. Neurotoxicol Teratol 29:37-46. (Pubitemid 46205157)
2. Ali SF, Newport GD, Holson RR, Slikker W, Bowyer JF. 1994. Low environmental temperature or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res 658:33-38.
3. Battaglia G, Yeh SY, De Souza EB. 1988. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 29:269-274. (Pubitemid 19258259)
4. Baumann MH, Wang X, Rothman RB. 2007. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: A reappraisal of past and present findings. Psychopharmacology 189:407-424. (Pubitemid 44791212)
5. Bilsky EJ, Hubbell CL, Delconte JD, Reid LD. 1991. MDMA produces a conditioned place preference and elicits ejaculation in male rats: A modulatory role for the endogenous opioids. Pharmacol Biochem Behav 40:443-447.
6. Breslau K. 2002. The 'sextasy' craze: Clubland's dangerous party mix: Viagra and ecstasy. Newsweek 139:30.
7. Broening HW, Bowyer JF, Slikker W. 1995. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 275:325-333.
8. Cadet JL, Krasnova IN. 2009. Cellular and molecular neurobiology of brain preconditioning. Mol Neurobiol 39:50-61.
9. Clemens KJ, Cornish JL, Hunt GE, McGregor IS. 2007. Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats. Drug Alcohol Depend 86:183-190.
10. Copeland J, Dillon P, Gascoigne M. 2006. Ecstasy and the concomitant use of pharmaceuticals. Addict Behav 31:367-370.
11. Cowan RL. 2007. Neuroimaging research in human MDMA users: A review. Psychopharmacology 189:539-556. (Pubitemid 44791223)
12. de Groat WC. 2006. Integrative control of the lower urinary tract: Clinical perspective. Brit J Pharmacol 147:S25-S40.
13. Escobedo I, Peraile I, Orio L, Colado MI, O'Shea E. 2007. Evidence for a role of Hsp70 in the neuroprotection induced by heat shock pre-treatment against 3,4-methylenedioxymethamphetamine toxicity in rat brain. J Neurochem 101:1272-1283.
14. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ulrich T, Rice KC, Woods JH. 2003. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 166:202-211.
15. Giuliano F. 2007. 5-hydroxytryptamine in premature ejaculation: Opportunities for therapeutic intervention. Trends Neurosci 30:79-84. (Pubitemid 46164860)
16. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 55:463-508. (Pubitemid 37013213)
17. Green AR, O'Shea E, Colado MI. 2004. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 500:3-13.
18. Hardman HF, Haavik CO, Seevers MH. 1973. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 25:299-309.
19. Kalivas PW, Duffy P, White SR. 1998. MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 18:469-479. (Pubitemid 28202354)
20. Kelly PA, Ritchie IM, Quate L, McBean DE, Olverman HJ. 2002. Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol 137:963-970. (Pubitemid 35440736)
21. Kindlundh-Högberg AM, Svenningsson P, Schiöth HB. 2006. Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain. Neuropharmacology 51:838-847.
22. Kindlundh-Högberg AMS, Schiöth HB, Svenningsson P. 2007. Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain. NeuroToxicology 28:1158-1169. (Pubitemid 350026594)
23. Kobeissy FH, Jeung JA, Warren MW, Geier JE, Gold MS. 2008. Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats. Addict Biol 13:15-25.
24. Lyles L, Cadet JL. 2003. Methylenedioxymethamphetamine (MDMA, Ecstasy) neurtoxicity: Cellular and molecular mechanisms. Brain Res Rev 42:155-168.
25. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM, Cornish JL, Hunt GE. 2003. Increased anxiety and "depressive" symptoms months after MDMA ("Ecstasy") in rats: Drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology 168:465-474. (Pubitemid 36994030)
26. Meyer JS, Grande K, Johnson K, Ali SF. 2004. Neurotoxic effects of MDMA ("ecstasy") administration to neonatal rats. Int J Dev Neurosci 22:261-271.
27. Meyer JS, Piper BJ, Vancollie VE. 2008. Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. Ann N Y Acad Sci 1139:151-163.
28. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. 1988. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. J Neurosci 8:2788-2803.
29. O'Shea E, Granados R, Esteban B, Colado MI, Green AR. 1998. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37:919-926.
30. Parrott AC. 2002. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837-844.
31. Parrott AC. 2005. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19:71-83.
32. Piper BJ. 2007. A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol Teratol 29:288-300.
33. Piper BJ, Meyer JS. 2004. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav 79:723-731.
34. Piper BJ, Fraiman JB, Meyer JS. 2005. Repeated MDMA ("Ecstasy") exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter binding. Dev Psychobiol 47:145-157.
35. 1A receptor agonist. J Pharmacol Exp Ther 317:838-849.
36. Piper BJ, Fraiman JB, Owens CB, Ali SF, Meyer JS. 2008. Dissociation of the neurochemical and behavioral consequences of MDMA ("Ecstasy") by citalopram. Neuropsychopharmacology 33:1192-1205.
37. Quinton MS, Yamamoto BK. 2006. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 8:E337-E347.
38. Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ. 2006. Neuroimaging findings with MDMA/ecstasy: Technical aspects, conceptual issues and future prospects. J Psychopharmacol 20:164-175.
39. Rènyi L. 1985. Ejaculations induced by p-chloroamphetamine in the rat. Neuropharmacology 24:697-704.
40. Rényi L. 1986. The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat. Br J Pharmacol 88:827-835.
41. Seiden LS, Woolverton WL, Lorens SA, Williams JE, Corwin RL, Hata N, Olimski M. 1993. Behavioral consequences of partial monoamine depletion in the CNS after methamphetamine-like drugs: The conflict between pharmacology and toxicology. NIDA Res Monogr 136:34-46.
42. Shpargel KB, Jalabi W, Yongming J, Dadabayev A, Penn MS, Trapp BD. 2008. Preconditioning paradigms and pathways in the brain. Cleveland Clin J Med 75(Suppl 2):S77-S82.
43. Soar K, Turner JJ, Parrott AC. 2006. Problematic versus non-problematic ecstasy/MDMA use: The influence of drug usage patterns and pre-existing psychiatric factors. J Psychopharmacol 20:417-424.
44. Spanos LJ, Yamamoto BK. 1989. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 32:835-840.
45. Sterk CE, Theall KP, Elifson KW. 2007. Getting into Ecstasy: Comparing moderate and heavy young adult users. J Psychoactive Drugs 39:103-113.
46. Stone DM, Hanson GR, Gibb JW. 1987. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26:1657-1661.
47. Wolters JP, Hellstrom WJ. 2006. Current concepts in ejaculatory dysfunction. Rev Urol 8 (Suppl 4):S18-S25.
48. Yamamoto BK, Bankson MG. 2005. Amphetamine neurotoxicity: Cause and consequence of oxidative stress. Crit RevNeurobiol 17:87-118.
49. Yonezawa A, Yoshizumi M, Ebiko M, Iwanaga T, Kimura Y, Sakurada S. 2005. Evidence for an involvement of peripheral serotonin in p-chloroamphetamine- induced ejaculation of rats. Pharmacol Biochem Behav 82:744-750. (Pubitemid 43184053)